A

Aegirbio AB
STO:AEGIR

Watchlist Manager
Aegirbio AB
STO:AEGIR
Watchlist
Price: 0.2235 SEK -1.97% Market Closed
Market Cap: 6.3m SEK

Aegirbio AB
Net Income (Common)

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Aegirbio AB
Net Income (Common) Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Net Income (Common) CAGR 3Y CAGR 5Y CAGR 10Y
A
Aegirbio AB
STO:AEGIR
Net Income (Common)
-kr59.7m
CAGR 3-Years
-48%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Biogaia AB
STO:BIOG B
Net Income (Common)
kr315.9m
CAGR 3-Years
5%
CAGR 5-Years
10%
CAGR 10-Years
N/A
Bonesupport Holding AB
STO:BONEX
Net Income (Common)
kr151.9m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Vitrolife AB
STO:VITR
Net Income (Common)
kr441m
CAGR 3-Years
8%
CAGR 5-Years
10%
CAGR 10-Years
11%
Swedish Orphan Biovitrum AB (publ)
STO:SOBI
Net Income (Common)
kr14m
CAGR 3-Years
-82%
CAGR 5-Years
-66%
CAGR 10-Years
-14%
BioArctic AB
STO:BIOA B
Net Income (Common)
-kr177.1m
CAGR 3-Years
-14%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Aegirbio AB
Glance View

Market Cap
6.9m SEK
Industry
Biotechnology

AegirBio AB engages in the development and commercialization of drug monitoring tests. The company is headquartered in Lund, Skane. The company went IPO on 2020-06-26. The firm offers tests to monitor and optimize the dosage of biological drugs via its patented technology platform. The company aims to provide personalized treatment by tracking drugs levels in individuals. Aegirbio combines core technologies from LifeAssays and Abreos Biosciences. LifeAssays is a diagnostics company based in Sweden, which owns the Magnia Point of Care and Point of Need reader technology. Abreos Biosciences is a California-based biotech, which is a developer of the Veritope chemistry platform for detecting levels of biologic drugs in patient samples.

AEGIR Intrinsic Value
Not Available
A

See Also

What is Aegirbio AB's Net Income (Common)?
Net Income (Common)
-59.7m SEK

Based on the financial report for Dec 31, 2023, Aegirbio AB's Net Income (Common) amounts to -59.7m SEK.

What is Aegirbio AB's Net Income (Common) growth rate?
Net Income (Common) CAGR 3Y
-48%

Over the last year, the Net Income (Common) growth was 84%. The average annual Net Income (Common) growth rates for Aegirbio AB have been -48% over the past three years .

Back to Top